ZIEXTENZO Q Code: Q5120

Drug & Product Overview

HCPCS Descriptor Injection, pegfilgrastim-bmez (ziextenzo), biosimilar, 0.5 mg

HCPCS Added Date July 1, 2020

Manufacturer Sandoz

Route of Administration Subcutaneous

Generic Status Single-Source; Branded

Dosage Type Single-Dose

Dosage Form Injection

About ZIEXTENZO

Ziextenzo is a medication aligned to the HCPCS Q Code: Q5120 for billing, pricing, and reimbursement purposes in the United States. This Oncology Colony Stimulating Factor medication is administered via the subcutaneous route and manufactured by Sandoz.

According to CMS Drug Use Information: Pegfilgrastim is a man-made version of a certain natural substance made by your body. It is used to help your body make more white blood cells. White blood cells are important to help you fight off infections. Pegfilgrastim is given to people whose ability to make white blood cells is reduced due to chemotherapy. Some brands may also be used to increase white blood cells after exposure to large amounts of radiation. This monograph is about the following pegfilgrastim products: pegfilgrastim, pegfilgrastim-apgf, pegfilgrastim-bmez, pegfilgrastim-cbqv, pegfilgrastim-fpgk, pegfilgrastim-jmdb, and pegfilgrastim-pbbk.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
61314-0866-01	Ziextenzo	Sandoz Inc.	12	6 MG / 0.6 ML
61314-0866-02	Ziextenzo	Sandoz Inc	12	6 MG / 0.6 ML

Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

ZIEXTENZO Pricing & Reimbursement

Q5120 Private Payer Reimbursement

$125.58 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Historical Graphing and Billing Calculator

per HCPCS unit

As of Q3 2026

Pegfilgrastim Biosimilar Information:

ZIEXTENZO Approval Date: November 4, 2019

Product Name	HCPCS Code	Active Ingredient	BLA Type
Neulasta	J2506	Pegfilgrastim	351(a) Originator Product
Fulphila	Q5108	Pegfilgrastim	351(k) Biosimilar
Udenyca	Q5111	Pegfilgrastim	351(k) Biosimilar
Ziextenzo	Q5120	Pegfilgrastim	351(k) Biosimilar
Nyvepria	Q5122	Pegfilgrastim	351(k) Biosimilar
Fylnetra	Q5130	Pegfilgrastim	351(k) Biosimilar
Stimufend	Q5127	Pegfilgrastim	351(k) Biosimilar
Armlupeg	Q5169	Pegfilgrastim	351(k) Biosimilar
Ennumo	N/A	Pegfilgrastim	351(k) Biosimilar

ZIEXTENZO Claims Performance

Claims from Jan 2026 – Aug 2026

Claim Denial Rate 21.87%

Avg. Days to File 13.4days

Avg. Days to Pay 19.1days

Real-world claims performance from FocalPoint, OnPoint Oncology's reimbursement analytics platform, with claims data accrued at the clearing house level.

Explore Q5120 claims analytics on FocalPoint →

ZIEXTENZO CPT Administration Codes

CPT Code	Description
96372	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intramuscular

JW / JZ modifiers apply

CMS has identified Ziextenzo (Q5120) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. Wastage billing guide →

ZIEXTENZO Medically Unlikely Edits (MUE)

The most billing units of Q5120 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 0.5 mg.

Practitioner Office & Hospital Outpatient

12 units / day

= 6 mg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

ZIEXTENZO Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Hematopoietic subsyndrome of acute radiation syndrome Patients with cancer receiving myelosuppressive chemotherapy

Drug Class

Granulocyte Colony-Stimulating Factor [CS]Increased Myeloid Cell Production [PE]Leukocyte Growth Factor [EPC]

Frequently Asked Questions

Is there an available Ziextenzo billing and coding guide?

Our team has not identified a manufacturer-published source of billing and coding information for ZIEXTENZO.

Are there any available Ziextenzo patient assistance programs?

Our team has not identified a manufacturer-published source of patient assistance information for ZIEXTENZO.

Where can I find Ziextenzo prescribing information?

ZIEXTENZO prescribing information can be found at the link below: Visit Here →

Where can I find Ziextenzo side effect information?

Information regarding ZIEXTENZO's side effects can be found at MedlinePlus Visit Here →

Does billing ZIEXTENZO require JZ/JW wastage modifiers?

CMS has identified ZIEXTENZO(Q5120) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. See CMS guidelines on use of the JZ and JW wastage modifiers below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.